Results 11 to 20 of about 718 (128)

Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens [PDF]

Journal of Fungi, 2022
Invasive fungal infections have mortality rates of 30–90%, depending on patient co-morbidities and the causative pathogen. The frequent emergence of drug resistance reduces the efficacy of currently approved treatment options, highlighting an urgent need
Sean D. Liston, Luke Whitesell, Mili Kapoor, Karen J. Shaw, Leah E. Cowen   +4 more
doaj   +2 more sources

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +2 more sources

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

Infection and Drug Resistance, 2023
Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj   +2 more sources

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +2 more sources

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments [PDF]

Journal of Fungi, 2020
Invasive fungal infections are associated with significant morbidity and mortality, and their management is restricted to a variety of agents from five established classes of antifungal medication.
Thomas J. Gintjee, Monica A. Donnelley, George R. Thompson   +2 more
doaj   +2 more sources

Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches [PDF]

Infection and Drug Resistance, 2021
Anna Maria Tortorano,1 Anna Prigitano,1 Gianluca Morroni,2 Lucia Brescini,2,3 Francesco Barchiesi2,4 1Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milano, Italy; 2Department of Biomedical Sciences and Public Health ...
Tortorano AM, Prigitano A, Morroni G, Brescini L, Barchiesi F   +4 more
doaj   +2 more sources

Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro [PDF]

, 2023
Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C.
DD Thomson (21935480), LLH John (21953459), M Hoenigl (21839471), EM Bignell (21953462), TS Harrison (21482639), T Bicanic (18374478), AJP Brown (21862340)   +6 more
core   +9 more sources

Molecular Mechanisms, Diagnosis, and Therapeutic Strategies of Antifungal Resistance in Filamentous Fungi

Journal of Fungi
Antifungal resistance in filamentous fungi has emerged as a major threat to global public health, posing a serious challenge particularly to immunocompromised populations. This review provides a systematic overview of the molecular mechanisms, diagnostic
Yajing Yin, Yueru Zhao, Meng Zhao, Lipeng Zhang, Ruijie Li, Lei Liu   +5 more
doaj   +2 more sources

Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment

Pathogens
Candidemia is a highly prevalent invasive fungal infection caused primarily by C. albicans, C. parapsilosis, C. glabrata (currently Nakaseomyces glabratus), C. tropicalis, and C. krusei (currently Pichia kudriavzevii). Risk factors for the development of
Juan Pablo Cabrera-Guerrero, Eduardo García-Salazar, Graciela Hernandez Silva, Alberto Chinney Herrera, Erick Martínez-Herrera, Rodolfo Pinto-Almazán, María Guadalupe Frías-De-León, Carlos Alberto Castro-Fuentes   +7 more
doaj   +2 more sources

Use of Expanded Access Fosmanogepix in Two Pediatric Patients With Rhino-Orbital-Cerebral Mucormycosis. [PDF]

Pharmacotherapy
Mucormycosis is a severe fungal infection with high morbidity and mortality. Pharmacotherapeutic options are limited, often used in combination, and associated with significant adverse effects.
Oldham MM, Buckendorf G, Elmitwalli I, Sparling DP, Tyungu DL.   +4 more
europepmc   +2 more sources